This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Salloum, R. M. Articles by Weichselbaum, R. R. Search for Related Content PubMed PubMed Citation Articles by Salloum, R. M. Articles by Weichselbaum, R. R.

NM-3, an Isocoumarin, Increases the Antitumor Effects of Radiotherapy without Toxicity¹

Departments of Surgery [R. M. S., N. T. J., V. K. G., M. C. P.] and Radiation and Cellular Oncology [H. J. M., S. S., M. A. B., A. M. K., D. M. H., S. H., R. R. W.], University of Chicago, Chicago, Illinois 60637; IlEX Oncology Inc., Boston, Massachusetts 02215 [C. R., R. K.]; and Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115 [D. W. K.]

We examined the effects of a new antiangiogenic isocoumarin, NM-3, as a radiation modifier in vitro and in vivo. The present studies demonstrate that NM-3 is cytotoxic to human umbilical vein endothelial cells (HUVECs) but not to Lewis lung carcinoma (LLC) cells nor Seg-1, esophageal adenocarcinoma cells, in clonogenic survival assays. When HUVEC cultures are treated with NM-3 combined with ionizing radiation (IR), additive cytotoxicity is observed. In addition, the combination of NM-3 and IR inhibits HUVEC migration to a greater extent than either treatment alone. The effects of treatment with NM-3 and IR were also evaluated in tumor model systems. C57BL/6 female mice bearing LLC tumors were given injections for 4 consecutive days with NM-3 (25 mg/kg/day) and treated with IR (20 Gy) for 2 consecutive days. Combined treatment with NM-3 and IR significantly reduced mean tumor volume compared with either treatment alone. An increase in local tumor control was also observed in LLC tumors in mice receiving NM-3/IR therapy. When athymic nude mice bearing Seg-1 tumor xenografts were treated with NM-3 (100 mg/kg/day for 4 days) and 20 Gy (four 5 Gy fractions), significant tumor regression was observed after combined treatment (NM-3 and IR) compared with IR alone. Importantly, no increase in systemic or local tissue toxicity was observed after combined treatment (NM-3 and IR) when compared with IR alone. The bioavailability and nontoxic profile of NM-3 suggests that the efficacy of this agent should be tested in clinical radiotherapy.

This article has been cited by other articles:

				N. N. Khodarev, A. J. Minn, E. V. Efimova, T. E. Darga, E. Labay, M. Beckett, H. J. Mauceri, B. Roizman, and R. R. Weichselbaum Signal Transducer and Activator of Transcription 1 Regulates Both Cytotoxic and Prosurvival Functions in Tumor Cells Cancer Res., October 1, 2007; 67(19): 9214 - 9220. [Abstract] [Full Text] [PDF]

				B. Yamini, X. Yu, M. E. Dolan, M. H. Wu, D. W. Kufe, and R. R. Weichselbaum Inhibition of Nuclear Factor-{kappa}B Activity by Temozolomide Involves O6-Methylguanine Induced Inhibition of p65 DNA Binding Cancer Res., July 15, 2007; 67(14): 6889 - 6898. [Abstract] [Full Text] [PDF]

				K. Ichinose, Y. Maeshima, Y. Yamamoto, M. Kinomura, K. Hirokoshi, H. Kitayama, Y. Takazawa, H. Sugiyama, Y. Yamasaki, N. Agata, et al. 2-(8-Hydroxy-6-Methoxy-1-Oxo-1H-2-Benzopyran-3-yl) Propionic Acid, an Inhibitor of Angiogenesis, Ameliorates Renal Alterations in Obese Type 2 Diabetic Mice. Diabetes, May 1, 2006; 55(5): 1232 - 1242. [Abstract] [Full Text] [PDF]

				N. Agata, H. Nogi, M. Milhollen, S. Kharbanda, and D. Kufe 2-(8-Hydroxy-6-methoxy-1-oxo-1H-2-benzopyran-3-yl)propionic Acid, a Small Molecule Isocoumarin, Potentiates Dexamethasone-Induced Apoptosis of Human Multiple Myeloma Cells Cancer Res., December 1, 2004; 64(23): 8512 - 8516. [Abstract] [Full Text] [PDF]

				E. K. Rofstad, K. Henriksen, K. Galappathi, and B. Mathiesen Antiangiogenic Treatment with Thrombospondin-1 Enhances Primary Tumor Radiation Response and Prevents Growth of Dormant Pulmonary Micrometastases after Curative Radiation Therapy in Human Melanoma Xenografts Cancer Res., July 15, 2003; 63(14): 4055 - 4061. [Abstract] [Full Text] [PDF]

				B. B.Y. Ma, R. G. Bristow, J. Kim, and L. L. Siu Combined-Modality Treatment of Solid Tumors Using Radiotherapy and Molecular Targeted Agents J. Clin. Oncol., July 15, 2003; 21(14): 2760 - 2776. [Abstract] [Full Text] [PDF]

				P. Sonveaux, A. Brouet, X. Havaux, V. Gregoire, C. Dessy, J.-L. Balligand, and O. Feron Irradiation-induced Angiogenesis through the Up-Regulation of the Nitric Oxide Pathway: Implications for Tumor Radiotherapy Cancer Res., March 1, 2003; 63(5): 1012 - 1019. [Abstract] [Full Text] [PDF]

				P. A. Burke, S. J. DeNardo, L. A. Miers, K. R. Lamborn, S. Matzku, and G. L. DeNardo Cilengitide Targeting of {alpha}v{beta}3 Integrin Receptor Synergizes with Radioimmunotherapy to Increase Efficacy and Apoptosis in Breast Cancer Xenografts Cancer Res., August 1, 2002; 62(15): 4263 - 4272. [Abstract] [Full Text] [PDF]

				R. J. Griffin, B. W. Williams, R. Wild, J. M. Cherrington, H. Park, and C. W. Song Simultaneous Inhibition of the Receptor Kinase Activity of Vascular Endothelial, Fibroblast, and Platelet-derived Growth Factors Suppresses Tumor Growth and Enhances Tumor Radiation Response Cancer Res., March 1, 2002; 62(6): 1702 - 1706. [Abstract] [Full Text] [PDF]

				C. L. Reimer, N. Agata, J. G. Tammam, M. Bamberg, W. M. Dickerson, G. D. Kamphaus, S. L. Rook, M. Milhollen, R. Fram, R. Kalluri, et al. Antineoplastic Effects of Chemotherapeutic Agents Are Potentiated by NM-3, an Inhibitor of Angiogenesis Cancer Res., February 1, 2002; 62(3): 789 - 795. [Abstract] [Full Text] [PDF]

				L. Yin, T. Ohno, R. Weichselbaum, S. Kharbanda, and D. Kufe The Novel Isocoumarin 2-(8-Hydroxy-6-methoxy-1-oxo-1H -2-benzopyran-3-yl) Propionic Acid (NM-3) Induces Lethality of Human Carcinoma Cells by Generation of Reactive Oxygen Species Mol. Cancer Ther., November 1, 2001; 1(1): 43 - 48. [Abstract] [Full Text] [PDF]